Could valproic acid be an effective anticancer agent? The evidence so far

Expert Review of Anticancer Therapy

Volumn 14, Issue 10, 2014, Pages 1097-1100

  Brodie, Seth A ^a,b,c   Brandes, Johann C ^a,b,c  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

AML; cancer prevention; HDAC; MDS; methylation; valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CISPLATIN; COSITECAN; CYCLOPHOSPHAMIDE; DNA METHYLTRANSFERASE 1; DOXORUBICIN; ENTINOSTAT; EPIRUBICIN; FLUOROURACIL; HISTONE H3; HYDRALAZINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOTCH1 RECEPTOR; RETINOIC ACID; TOPOTECAN; VALPROIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLADDER CANCER; BREAST METASTASIS; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CHROMATIN STRUCTURE; COLON CANCER; DEMETHYLATION; DNA METHYLATION; DRUG POTENTIATION; EPIGENETICS; HEAD AND NECK CANCER; HISTONE ACETYLATION; HUMAN; LUNG CANCER; MELANOMA; MESOTHELIOMA; METASTATIC MELANOMA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; DRUG EFFECTS; ENZYMOLOGY; GENETIC EPIGENESIS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; VALPROIC ACID;

EID: 84907518851     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.940329     Document Type: Review

References (22)

1. Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22: 3411-20
2. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64: 1079-86
3. Mohammed TA, Holen KD, Jaskula-Sztul R, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 2011;16:835-43
4. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-Trans retinoic acid. Cancer 2005;104:101-9
5. Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-Trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005; 84(Suppl 1):61-6
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9
8. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasiarelated changes: Results of the US Leukemia Intergroup Trial E1905. J Clin Oncol 2014;32:1242-8
9. Chu BF, Karpenko MJ, Liu Z, et al. Phase I study of 5-Aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 2013;71:115-21
10. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607
11. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study. J Clin Oncol 2007;25: 1979-85
12. Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: Phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009;15:2488-96
13. Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011;37: 129-35
14. Daud AI, Dawson J, DeConti RC, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: Translational and phase I/II clinical trial. Clin Cancer Res 2009;15:2479-87
15. Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2011; 28(Suppl 1):S540-6
16. Falchook GS, Fu S, Naing A, et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 2013;31: 1192-200
17. Juengel E, Dauselt A, Makarevic J, et al. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett 2012;324:83-90
18. Du Z, Song J, Wang Y, et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal 2010;3:ra80
19. Brodie SA, Li G, El-Kommos A, et al. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila) 2014;7:351-61
20. Kang H, Gillespie TW, Goodman M, et al. Long-Term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer 2014;120:1394-400
21. Hallas J, Friis S, Bjerrum L, et al. Cancer risk in long-Term users of valproate: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2009;18:1714-19
22. Singh G, Bell GS, Driever PH, Sander JW. Cancer risk in people with epilepsy using valproate sodium. Acta Neurol Scand 2012;125:234-40